Dexfenfluramine for weight gain secondary to psychotropics.
We describe the use of dexfenfluramine (Redux) in six patients with mood disorders (bipolar disorder = 3; major depression = 3) who developed significant weight gain as a result of their psychotropics. All patients were females with an age range of 27-58 years. The duration of the trial varied from 3 to 20 weeks, with the dexfenfluramine dosage being 15 mg twice daily. Weight loss ranged from 2 to 23 pounds. None of the patients had any evidence of primary pulmonary hypertension or serotonin syndrome, despite being on serotonergic agents such as fluoxetine, paroxetine, and sertraline.
Masand
P S
PS
Department of Psychiatry, SUNY Health Science Center at Syracuse 13210, USA.
Gupta
S
S
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D018490:Serotonin Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects
D000928:Antidepressive Agents; D001067:Appetite Depressants; D018490:Serotonin Agents; D005277:Fenfluramine